-transparent.png){kind=logo}
The trial included 155 patients with destructive pulmonary tuberculosis: 60 on conventional antibacterial therapy (isoniazid, rifampicin, streptomycin), 95 on intensive chemotherapy (isoniazid, rifampicin, streptomycin, pirazinamid or ethambutol, vitamins for initial 2-3 months). 69 patients from the latter group received adjuvant antioxidants (tocopherol acetate or galascorbin) in combination with one of the antihypoxants (piracetam, calcii pangamas, piriditol). The intensive chemotherapy promoted a decrease in duration of bacterial discharge, destruction discontimation, cavernous healing, reduced incidence rates of side effects. Metabolic processes characterizing lipid peroxidation and redox improved.
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1988,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
November 1979,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1994,
Terapevticheskii arkhiv,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1971,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
July 1983,
Vrachebnoe delo,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1975,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1985,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
February 1983,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1986,
Problemy tuberkuleza,
M M Savula, and
N S Kravchenko, and
A I Poznanskiĭ
January 1972,
Vrachebnoe delo,
